Chapter 11 Production of Recombinant Proteoliposomes for Therapeutic Uses

Methods in Enzymology

Volumn 465, Issue C, 2009, Pages 209-223

  Liguori, Lavinia ^a   Lenormand, Jean Luc ^a  

^a LABORATOIRE TIMC IMAG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; LIPOSOME; MEMBRANE PROTEIN; PROTEIN BAK; RECOMBINANT PROTEOLIPOSOME; UNCLASSIFIED DRUG; BAK1 PROTEIN, HUMAN; PROTEOLIPID; PROTEOLIPOSOMES; RECOMBINANT PROTEIN;

ANIMAL CELL; APOPTOSIS; BIOCOMPATIBILITY; CANCER CELL; CELL FREE SYSTEM; CELL MEMBRANE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME ACTIVATION; EUKARYOTIC CELL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE VECTOR; LARGE SCALE PRODUCTION; LIPID COMPOSITION; LIPOGENESIS; LIPOSOMAL DELIVERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PROTEOLIPOSOME; REVIEW; TRANSMISSION ELECTRON MICROSCOPY; ARTICLE; BIOSYNTHESIS; ESCHERICHIA COLI; GENETICS; HUMAN; METABOLISM; POLYMERASE CHAIN REACTION;

BACTERIA (MICROORGANISMS); EUKARYOTA;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CASPASE 9; CELL-FREE SYSTEM; ENZYME ACTIVATION; ESCHERICHIA COLI; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; POLYMERASE CHAIN REACTION; PROTEOLIPIDS; RECOMBINANT PROTEINS;

EID: 71849101080     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(09)65011-4     Document Type: Review

References (33)

1. Düzgüneş N., Simões S., Konopka K., Rossi J.J., and Pedroso de Lima M.C. Delivery of novel macromolecular drugs against HIV-1. Expert Opin. Biol. Ther. 1 (2001) 949-970
2. Düzgüneş N., Simões S., Slepushkin V., Pretzer E., Flasher D., Salem I.I., Steffan G., Konopka K., and Pedroso de Lima M.C. Delivery of antiviral agents in liposomes. Methods Enzymol. 391 (2005) 351-373
3. Düzgüneş N., Simões S., Lopez-Mesas M., and Pedroso de Lima M.C. Intracellular delivery of therapeutic oligonucleotides in pH-sensitive and cationic liposomes. In: Gregoriadis G. (Ed). Liposome Technology. Vol. III (2007), Informa Healthcare USA, New York 253-275
4. Fantin V.R., and Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 25 (2006) 4787-4797
5. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5 (2005) 876-885
6. Galluzzi L., Larochette N., Zamzami N., and Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25 (2006) 4812-4830
7. Gupta S., Kass G.E., Szegezdi E., and Joseph B. The mitochondrial death pathway: A promising therapeutic target in diseases. J. Cell. Mol. Med. 13 6 (2009) 1004-1033
8. Hemmati P.G., Guner D., Gillissen B., Wendt J., von Haefen C., Chinnadurai G., Dorken B., et al. Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells. Oncogene 25 (2006) 6582-6594
9. Kamps J.A., Koning G.A., Velinova M.J., Morselt H.W., Wilkens M., Gorter A., Donga J., and Scherphof G.L. Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancer. J. Drug Target. 8 (2000) 235-245
10. Klammt C., Lohr F., Schafer B., Haase W., Dotsch V., Ruterjans H., Glaubitz C., et al. High level cell-free expression and specific labeling of integral membrane proteins. Eur. J. Biochem. 271 (2004) 568-580
11. Klammt C., Schwarz D., Fendler K., Haase W., Dotsch V., and Bernhard F. Evaluation of detergents for the soluble expression of alpha-helical and beta-barrel-type integral membrane proteins by a preparative scale individual cell-free expression system. FEBS J. 272 (2005) 6024-6038
12. Leader B., Baca Q.J., and Golan D.E. Protein therapeutics: A summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008) 21-40
13. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., and Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (2002) 183-192
14. Liguori L., Marques B., and Lenormand J.L. A bacterial cell-free expression system to produce membrane proteins and proteoliposomes: From cDNA to functional assay. Curr. Protoc. Protein Sci. (2008) Chapter 5: Unit 5.22
15. Liguori L., Marques B., Villegas-Mendez A., Rothe R., and Lenormand J.L. Liposomes-mediated delivery of pro-apoptotic therapeutic membrane proteins. J. Control. Release 126 (2008) 217-227
16. Lukyanov A.N., Elbayoumi T.A., Chakilam A.R., and Torchilin V.P. Tumor-targeted liposomes: Doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Control. Release 100 (2004) 135-144
17. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 65 (2000) 271-284
18. Maeda H., Bharate G.Y., and Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71 (2009) 409-419
19. Marques B., Liguori L., Paclet M.H., Villegas-Mendez A., Rothe R., Morel F., and Lenormand J.L. Liposome-mediated cellular delivery of active gp91. PLoS ONE 2 (2007) e856
20. Pavlou A.K., and Reichert J.M. Recombinant protein therapeutics-Success rates, market trends and values to 2010. Nat. Biotechnol. 22 (2004) 1513-1519
21. Reed J.C. Proapoptotic multidomain Bcl-2/Bax-family proteins: Mechanisms, physiological roles, and therapeutic opportunities. Cell Death Differ. 13 (2006) 1378-1386
22. Salem I.I., Flasher D.L., and Düzgüneş N. Liposome-encapsulated antibiotics. Methods Enzymol. 391 (2005) 261-291
23. Spirin A.S. High-throughput cell-free systems for synthesis of functionally active proteins. Trends Biotechnol. 22 (2004) 538-545
24. Swartz J.R., Jewett M.C., and Woodrow K.A. Cell-free protein synthesis with prokaryotic combined transcription-translation. Methods Mol. Biol. 267 (2004) 169-182
25. Tauzin B. Biotechnology research continues to bolster arsenal against disease with 633 medicines in development. Biotechnology (2008) 1-60
26. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
27. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 8 (2006) 343-375
28. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 9 (2007) 128-147
29. Vail D.M., Amantea M.A., Colbern G.T., Martin F.J., Hilger R.A., and Working P.K. Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol. 31 (2004) 16-35
30. Walensky L.D. BCL-2 in the crosshairs: Tipping the balance of life and death. Cell Death Differ. 13 (2006) 1339-1350
31. Walensky L.D., Pitter K., Morash J., Oh K.J., Barbuto S., Fisher J., Smith E., et al. A stapled BID BH3 helix directly binds and activates BAX. Mol. Cell 24 (2006) 199-210
32. Williams S.S., Alosco T.R., Mayhew E., Lasic D.D., Martin F.J., and Bankert R.B. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. 53 (1993) 3964-3967
33. Yin H., Lee G.I., Sedey K.A., Kutzki O., Park H.S., Orner B.P., Ernst J.T., et al. Terphenyl-based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J. Am. Chem. Soc. 127 (2005) 10191-10196